5-Amino-1MQ vs AOD-9604: What the Evidence Shows

What is being compared?

5-Amino-1MQ is a small-molecule inhibitor of nicotinamide N-methyltransferase (NNMT) investigated in metabolic research. AOD-9604 is a modified fragment of human growth hormone; FDA describes it as hGH residues 177–191 with an added N-terminal tyrosine. The compounds are chemically and biologically distinct. No direct trial in the evidence reviewed here compares their effects on human body weight. Neelakantan et al., 2018 · FDA AOD-9604 briefing, 2024

5-Amino-1MQ: preclinical metabolic findings

Neelakantan and colleagues identified 5-Amino-1MQ as an NNMT inhibitor and reported effects in cultured adipocytes. In diet-induced obese mice, treatment with a potent NNMT inhibitor reduced body weight and white adipose mass in that experimental setting. These cell and mouse observations do not supply a human efficacy or safety estimate. NNMT target biology cannot by itself establish a weight-loss treatment. Neelakantan et al., 2018, PMID 29155147

AOD-9604: the human obesity record

FDA’s 2024 advisory briefing summarizes the sponsor’s randomized, placebo-controlled OPTIONS phase 2b trial. It reports 536 adults enrolled and 502 randomized, with no statistically significant weight-loss difference versus placebo at the 12-week primary endpoint or at 24 weeks. FDA says the detailed study design and preliminary efficacy results do not appear to have been published in medical literature; this comparison therefore does not assign a precise percentage loss or claim an independent efficacy replication. FDA AOD-9604 briefing, 2024

A separate 2013 paper pooled safety observations from six sponsor-funded human studies, including OPTIONS. That publication does not change the negative phase 2b efficacy finding or establish long-term safety for a marketed formulation. Preclinical AOD-9604 lipid-metabolism findings likewise cannot substitute for a positive human weight-loss result. Stier et al., 2013 · Heffernan et al., 2001, PMID 11713213

What the evidence does not resolve

The two evidence sets cannot be converted into a comparative percentage, safety ranking, or treatment recommendation. The cited 5-Amino-1MQ experiment is preclinical. The AOD-9604 human study has a negative placebo-controlled efficacy result, while its detailed efficacy report is not published in the medical literature described by FDA. Neither result is a direct comparison with the other compound or with an approved obesity medicine. Neelakantan et al., 2018 · FDA AOD-9604 briefing, 2024

Regulatory context

The June 2026 Australian Poisons Standard names AOD-9604 in Schedule 4 and Appendix D clause 5. Those are substance-scheduling entries. They do not establish that an AOD-9604 product is included in the Australian Register of Therapeutic Goods (ARTG), available over the counter, or approved for weight loss. TGA guidance on therapeutic peptide products explains that product registration or listing is a separate question. This comparison does not determine whether any particular product has an ARTG entry.

FDA’s review of AOD-9604 for a compounding advisory process is also not an approval of a weight-loss medicine. This page does not assess a product-specific regulatory status for 5-Amino-1MQ. FDA AOD-9604 briefing, 2024

Reading the result

5-Amino-1MQ has mechanistic and animal findings but the cited primary experiment has no human weight-loss endpoint. AOD-9604 has human obesity data, including a larger phase 2b trial that did not demonstrate significant weight loss against placebo. The distinction is about what each source actually measured; it is not a ranking of which compound is more effective or safer. The linked 5-Amino-1MQ and AOD-9604 dossiers provide the source context for each compound.